This laboratory is committed to the definition of the molecular effects of retinoic acid and its derivatives (retinoids), that are non-conventional drugs with differentiating ability of breast and gastric cancer cells.
New diagnostic methods to select patients who may benefit most from retinoid-based treatments are also investigated. Moreover, this laboratory has previously determined the structure of genes encoding different molybdoenzymes.
The ongoing studies are aimed to define their physiological function.
Breast cancer: predictive diagnostic models for the clinical use of retinoic acid
Identification of predictive biomarkers able to select breast cancer patients who may benefit from retinoic acid-based therapies.
Clinical trials to test the efficacy of retinoid-based therapies against breast cancer
Phase III clinical trial in postmenopausal patients with estrogen receptor-positive breast cancer to assess the efficacy of adding retinoic acid to standard treatment.
Personalised therapy for breast cancer patients
Identification of protein networks specifically altered by retinoic acid in breast cancer cells to develop new therapeutic strategies based on drug combination as personalised treatments.
Preclinical study about retinoic acid against stomach cancer
Use of experimental models of stomach cancer to evaluate the therapeutic potential of retinoic acid in personalised treatments of this tumor type.
Studies about molybdoenzymes
Development of experimental models in vitro and in vivo aimed to define the physiological functions of the various members of the molybdoenzyme family.
International Consensus on Cardiopulmonary Resuscitation.